Clinical Trials Sponsored by Onconova Therapeutics, Inc.

Total 2941 results

Onconova Therapeutics, Inc.

Recruiting

Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies

Endometrioid Endometrial Cancer

United States
Onconova Therapeutics, Inc.

Completed

Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs

Myelodysplastic Syndromes

United States, France, Germany
Onconova Therapeutics, Inc.

Withdrawn

Three Dosing Schedules of Oral Rigosertib in MDS Patients

Myelodysplastic Syndrome

United States
Onconova Therapeutics, Inc.

Completed

Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients

Ovarian Cancer

United States
Onconova Therapeutics, Inc.

Completed

Oral Rigosertib for Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Anal Squamous Cell Carcinoma | Cervical Squamous Cell Carcinoma | Skin Squamous Cell Carcinoma | Lung Squamous Cell Carcinoma | Penile Squamous Cell Carcinoma

United States
Onconova Therapeutics, Inc.

Completed

Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
Onconova Therapeutics, Inc.

Completed

Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors

Solid Tumor

United States
Onconova Therapeutics, Inc.

Completed

Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin

Advanced Solid Tumors

United States
Onconova Therapeutics, Inc.

Completed

Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma

Advanced Solid Tumor | Hepatoma

United States
Onconova Therapeutics, Inc.

Completed

Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome

United States, France
Onconova Therapeutics, Inc.

Completed

Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine

Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | Cytopenia | Refractory Anemia With Excess Blasts

United States, Australia, Spain, Italy, Germany, France, Sweden, Denmark
Onconova Therapeutics, Inc.

Completed

Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)

Chronic Myeloid Leukemia | Acute Lymphocytic Leukemia | Acute Myelocytic Leukemia | Myeloproliferative Disease

United States
Onconova Therapeutics, Inc.

Completed

Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome (ONTARGET)

Myelodysplastic Syndrome | MDS | Trisomy 8

United States
Onconova Therapeutics, Inc.

Completed

Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer

Neoplasms | Cancer | Advanced Cancer | Solid Tumors

United States
Onconova Therapeutics, Inc.

Completed

Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer

Neoplasms | Cancer | Advanced Cancer | Solid Tumors

United States
Onconova Therapeutics, Inc.

Withdrawn

Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States
Onconova Therapeutics, Inc.

Terminated

Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia

Lymphoma | Acute Lymphocytic Leukemia

United States
Onconova Therapeutics, Inc.

Recruiting

Study of ON 123300 in Patients With Advanced Cancer

Solid Tumors, Adult

United States
Onconova Therapeutics, Inc.

Terminated

Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA (INSPIRE)

Myelodysplastic Syndrome | MDS | Refractory Anemia With Excess Blasts | RAEB

United States, Spain, Canada, France, Australia, Switzerland, Israel, Japan, Belgium, India, Ireland, United Kingdom, Croatia, Czechia, Poland, Estonia, Germany, Italy, Austria, Hungary, Russian Federation, Sweden
Onconova Therapeutics, Inc.

Terminated

Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors

Neoplasms | Advanced Solid Tumor

United States
Onconova Therapeutics, Inc.

Completed

Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes | Chronic Lymphocytic Leukemia | Chronic Myelocytic Leukemia | Acute Lymphocytic Leukemia | Acute Myelocytic Leukemia

United States
Onconova Therapeutics, Inc.

Completed

Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk

Myelodysplastic Syndrome

United States
Onconova Therapeutics, Inc.

Completed

Metabolism and Excretion of [14C]-Rigosertib After Infusion to Volunteers

Healthy

United States
Onconova Therapeutics, Inc.

Completed

Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer

Head and Neck Neoplasms | Carcinoma, Squamous Cell

United States
Onconova Therapeutics, Inc.

Completed

Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors

Solid Tumors | Malignant Neoplasmas

United States
Onconova Therapeutics, Inc.

Completed

Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States
Onconova Therapeutics, Inc.

Completed

Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors

Solid Tumor

United States
Thomas Jefferson University
Onconova Therapeutics, Inc.

Recruiting

Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC

Recessive Dystrophic Epidermolysis Bullosa

United States
M.D. Anderson Cancer Center
Onconova Therapeutics, Inc.

Terminated

Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia

Leukemia | Anemia | Myelofibrosis | Splenomegaly

United States
Onconova Therapeutics, Inc.
The Leukemia and Lymphoma Society

Completed

Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts (ONTIME)

Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | MDS | RAEB

United States, Belgium, Germany, Spain, France, Italy
Onconova Therapeutics, Inc.
Academic GI Cancer Consortium (AGICC)

Completed

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer (ONTRAC)

Metastatic Pancreatic Adenocarcinoma

United States, India, Russian Federation, Hungary, Ukraine
Icahn School of Medicine at Mount Sinai
Bristol-Myers Squibb; Onconova Therapeutics, Inc.

Recruiting

Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment

Adenocarcinoma | Non-small Cell Lung Cancer | Stage IV

United States
BlackThorn Therapeutics, Inc.
Neumora Therapeutics, Inc.

Completed

Study in Major Depressive Disorder With BTRX-335140 (NMRA-335140) vs Placebo

Major Depressive Disorder

United States
Sirion Therapeutics, Inc.
ReVision Therapeutics, Inc.

Completed

Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

Geographic Atrophy | Dry Age Related Macular Degeneration
Therapeutics, Inc.

Completed

Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis (307)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 310)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis

Psoriasis | Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis

Tinea Pedis | Tinea Cruris

United States
Therapeutics, Inc.

Completed

A Study of the Safety and Efficacy of UHE-105 Shampoo in Subjects With Scalp Psoriasis

Scalp Psoriasis

United States
Therapeutics, Inc.

Completed

A Phase 2 Safety and Efficacy Study of UHE-101 Cream in Subjects With Acne Vulgaris

Acne Vulgaris

United States
Therapeutics, Inc.

Completed

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 306)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis

Psoriasis | Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis

Tinea Pedis

United States, Puerto Rico
Therapeutics, Inc.

Completed

A Safety Study of 188-0551 Spray Versus Reference Listed Drug (RLD) in Adult Subjects With Plaque Psoriasis

Plaque Psoriasis

United States, Georgia, Ukraine
Therapeutics, Inc.

Completed

A Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis (305)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison of 188-0551 Solution Versus Vehicle Solution in Subjects With Plaque Psoriasis (Study 203)

Plaque Psoriasis

United States

Clinical Trials Sponsored by Onconova Therapeutics, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations